Physiological adaptation to hypoxic endurance training in physically active but non-competitive men Other
Conditions
Interventions
Participants are stratified by age, baseline functional capacity, anthropometric characteristics, and tolerance to hypoxic exposure, then allocated to one of four parallel groups using stratified rand
Sponsors
Research Institute of Geroprotective Technologies, Saint Petersburg, Russia
Eligibility
Sex/Gender
Male
Age
19 Years to 35 Years
Inclusion criteria
Inclusion criteria: 1. Healthy men aged 19–35 years 2. Body mass index (BMI) 21–28 kg/m² 3. Physically active but not competitive athletes, regularly engaged in recreational exercise (e.g., running, fitness training, swimming) 4. Written informed consent 5. Ability to maintain habitual physical activity throughout the study 6. Absence of cardiovascular, respiratory, metabolic, neurological, or psychiatric disease
Exclusion criteria
Exclusion criteria: Any condition that could compromise safety, adherence, or physiological responses to hypoxia or exercise
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Aerobic threshold measured using power output (W) during an incremental cycling test with stepwise increases starting at 50 W (25 W increments per stage), determined using combined ventilatory criteria (first disproportionate increase in V?E/V?O2 without concomitant rise in V?E/V?CO2, and changes in respiratory exchange ratio), assessed on an electronically braked cycle ergometer with breath-by-breath metabolic system (SCHILLER CARDIOVIT CS-200) at baseline (3 days before intervention), 3 days post-intervention and 3 weeks post-intervention | — |
Secondary
| Measure | Time frame |
|---|---|
| Hypoxic tolerance measured using breath-hold duration (s) during the Stange test (maximal breath hold at end-inspiration, seated position) at baseline (3 days before intervention), 3 days post-intervention and 3 weeks post-intervention;Ventilatory equivalent for oxygen measured using change in V?E/V?O2 during standardized normobaric hypoxic exposure, assessed via breath-by-breath metabolic system (SCHILLER CARDIOVIT CS-200) at averaged across training sessions 1-15;Peripheral oxygen saturation measured using change in SpO2 (%) during standardized normobaric hypoxic exposure, measured by pulse oximetry (MARG Microlux) at averaged across training sessions 1-15;Oxygen uptake measured using change in V?O2 (L·min?¹) during standardized normobaric hypoxic exposure, assessed via breath-by-breath metabolic system (SCHILLER CARDIOVIT CS-200) at averaged across training sessions 1-15;Cardiovascular cost during hypoxic exercise measured using change in heart rate (?HR, bpm) relative to normoxic resting values, recorded via wireless monitoring system (Polar) at training phases 1-5, 6-10, and 11-15;Tolerability measured using session completion rate, protocol modifications, and subjective symptom severity ratings; psychological well-being assessed using the SAN (Well-being-Activity-Mood) questionnaire at throughout the 15-session intervention | — |
Countries
Russian Federation
Contacts
Public ContactArseny Kuzmin
Outcome results
None listed